CCDC186

Summary

CCDC186 (coiled-coil domain containing 186, HGNC:24349) is a protein-coding gene on chromosome 10q25.3, encoding Coiled-coil domain-containing protein 186 (Q7Z3E2).

Predicted to enable small GTPase binding activity. Predicted to be involved in vesicle cytoskeletal trafficking. Predicted to act upstream of or within insulin secretion involved in cellular response to glucose stimulus and response to bacterium. Predicted to be located in Golgi apparatus. Predicted to be active in trans-Golgi network.

Source: NCBI Gene 55088 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 130 total — 2 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_018017

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24349
Approved symbol	CCDC186
Name	coiled-coil domain containing 186
Location	10q25.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10188, FLJ35301, CCCP-1, golgin104
Ensembl gene	ENSG00000165813
Ensembl biotype	protein_coding
OMIM	619249
Entrez	55088

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000369285, ENST00000369286, ENST00000369287, ENST00000428953, ENST00000490661, ENST00000497592, ENST00000648613, ENST00000912199

RefSeq mRNA: 3 — MANE Select: NM_018017 NM_001321829, NM_018017, NM_153249

CCDS: CCDS7587, CCDS81506

Canonical transcript exons

ENST00000369287 — 16 exons

Exon	Start	End
ENSE00000724795	114127461	114127671
ENSE00000724799	114129891	114129971
ENSE00001298678	114136148	114136246
ENSE00001300046	114134913	114135055
ENSE00001322127	114131929	114132184
ENSE00001340447	114125886	114126105
ENSE00001352806	114135891	114135977
ENSE00001352813	114137186	114137290
ENSE00001449416	114120862	114125226
ENSE00001677417	114157554	114157680
ENSE00001682905	114151092	114151220
ENSE00001710956	114144497	114144616
ENSE00001724445	114145549	114145761
ENSE00002497072	114162637	114163329
ENSE00003514147	114131147	114131336
ENSE00003842829	114174015	114174203

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 95.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.8799 / max 1176.9964, expressed in 1727 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
111471	16.2672	1725
111467	0.6126	204

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	95.96	gold quality
jejunal mucosa	UBERON:0000399	94.61	gold quality
calcaneal tendon	UBERON:0003701	93.64	gold quality
caput epididymis	UBERON:0004358	92.64	gold quality
upper leg skin	UBERON:0004262	92.06	gold quality
male germ cell	CL:0000015	91.97	gold quality
palpebral conjunctiva	UBERON:0001812	91.96	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.82	gold quality
buccal mucosa cell	CL:0002336	91.79	gold quality
colonic mucosa	UBERON:0000317	91.42	gold quality
colonic epithelium	UBERON:0000397	91.39	gold quality
oocyte	CL:0000023	91.38	gold quality
bronchial epithelial cell	CL:0002328	91.25	gold quality
amniotic fluid	UBERON:0000173	91.20	gold quality
skin of hip	UBERON:0001554	91.08	gold quality
body of pancreas	UBERON:0001150	90.38	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.33	gold quality
tendon	UBERON:0000043	90.05	gold quality
mucosa of paranasal sinus	UBERON:0005030	89.97	gold quality
corpus epididymis	UBERON:0004359	89.91	gold quality
oral cavity	UBERON:0000167	89.38	gold quality
rectum	UBERON:0001052	89.16	gold quality
seminal vesicle	UBERON:0000998	89.07	gold quality
tibia	UBERON:0000979	88.37	gold quality
esophagus squamous epithelium	UBERON:0006920	88.20	gold quality
pancreas	UBERON:0001264	88.03	gold quality
jejunum	UBERON:0002115	88.01	gold quality
tonsil	UBERON:0002372	87.98	gold quality
synovial joint	UBERON:0002217	87.80	gold quality
mammalian vulva	UBERON:0000997	87.47	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	15.58
E-MTAB-8498	yes	13.41
E-MTAB-9067	yes	12.12
E-MTAB-9388	yes	5.82
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

264 targeting CCDC186, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-LET-7A-3P	100.00	74.03	3932
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-6077	99.99	68.04	2299
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593

Literature-anchored findings (GeneRIF, showing 2)

• A homozygous truncating variant in CCDC186 in an individual with epileptic encephalopathy. (PMID:33259146)
• Functional Evidence of CCDC186 as a New Disease-Associated Gene with Endocrine and Central Nervous System Alterations. (PMID:37569695)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc186	ENSDARG00000061020
mus_musculus	Ccdc186	ENSMUSG00000035173
rattus_norvegicus	Ccdc186	ENSRNOG00000051680
drosophila_melanogaster	Golgin104	FBGN0036614
caenorhabditis_elegans		WBGENE00013042

Protein

Protein identifiers

Coiled-coil domain-containing protein 186 — Q7Z3E2 (reviewed: Q7Z3E2)

Alternative names: CTCL tumor antigen HD-CL-01/L14-2

All UniProt accessions (3): A0A0C4DFU7, Q7Z3E2, H0Y7V5

UniProt curated annotations — full annotation on UniProt →

RefSeq proteins (3): NP_001308758, NP_060487, NP_694981 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR038830	CCDC186	Family

UniProt features (21 total): sequence conflict 5, compositionally biased region 3, sequence variant 3, region of interest 3, coiled-coil region 3, modified residue 2, initiator methionine 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z3E2-F1	74.62	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 740

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 241 (showing top): GOBP_VESICLE_LOCALIZATION, GOBP_INSULIN_SECRETION, GOBP_CELLULAR_RESPONSE_TO_CARBOHYDRATE_STIMULUS, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT, AP4_Q6, GOMF_GTPASE_BINDING, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, CAGCTG_AP4_Q5, YY1_Q6, GOBP_CELL_CELL_SIGNALING, GOCC_TRANS_GOLGI_NETWORK, GOBP_VESICLE_CYTOSKELETAL_TRAFFICKING, KOYAMA_SEMA3B_TARGETS_UP, YY1_02

GO Biological Process (4): response to bacterium (GO:0009617), insulin secretion involved in cellular response to glucose stimulus (GO:0035773), vesicle cytoskeletal trafficking (GO:0099518), glucose homeostasis (GO:0042593)

GO Molecular Function (1): small GTPase binding (GO:0031267)

GO Cellular Component (2): trans-Golgi network (GO:0005802), Golgi apparatus (GO:0005794)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to other organism	1
insulin secretion	1
establishment of localization in cell	1
cellular response to glucose stimulus	1
cytoskeleton-dependent intracellular transport	1
establishment of vesicle localization	1
carbohydrate homeostasis	1
GTPase binding	1
Golgi apparatus subcompartment	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

678 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC186	EIPR1	Q53HC9	717
CCDC186	VPS50	Q96JG6	626
CCDC186	VPS54	Q9P1Q0	566
CCDC186	VPS51	Q9UID3	566
CCDC186	NHLRC2	Q8NBF2	566
CCDC186	RUNDC1	Q96C34	546
CCDC186	CCDC138	Q96M89	526
CCDC186	ICA1	P78506	491
CCDC186	RUFY1	Q96T51	485
CCDC186	PLEKHS1	Q5SXH7	474
CCDC186	TECTB	Q96PL2	463
CCDC186	ZDHHC6	Q9H6R6	460
CCDC186	CPD	O75976	452
CCDC186	ADRB1	P08588	449
CCDC186	RAB2A	P08886	448

IntAct

38 interactions, top by confidence:

A	B	Type	Score
SIKE1	SLMAP	psi-mi:“MI:0914”(association)	0.770
TEPSIN	AP4M1	psi-mi:“MI:0914”(association)	0.700
CCDC186		psi-mi:“MI:0915”(physical association)	0.550
YES1	AIP	psi-mi:“MI:0914”(association)	0.530
NUP62	RGPD8	psi-mi:“MI:0914”(association)	0.530
RAB27B	GBA1	psi-mi:“MI:0914”(association)	0.530
YES1	SERPINB2	psi-mi:“MI:0914”(association)	0.530
CCDC186	H1-4	psi-mi:“MI:0915”(physical association)	0.400
DUSP23	CCDC186	psi-mi:“MI:0915”(physical association)	0.370
GAMMAHV.ORF23	CCDC186	psi-mi:“MI:0915”(physical association)	0.370
Rassf1	TTC31	psi-mi:“MI:0914”(association)	0.350
Pten	MPZL1	psi-mi:“MI:0914”(association)	0.350
Ktn1	ESYT2	psi-mi:“MI:0914”(association)	0.350
TSNAXIP1	USO1	psi-mi:“MI:0914”(association)	0.350
RUNDC3A	GMNN	psi-mi:“MI:0914”(association)	0.350
RAB27B	GBA1	psi-mi:“MI:0914”(association)	0.350
	CCDC22	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
KRT38	KRBA1	psi-mi:“MI:0914”(association)	0.350
KRT27	CCDC88B	psi-mi:“MI:0914”(association)	0.350
KRT40	ANKRD36	psi-mi:“MI:0914”(association)	0.350
WHAMMP3	EXOC5	psi-mi:“MI:0914”(association)	0.350
DRC3	ZNF195	psi-mi:“MI:0914”(association)	0.350
RABEP1	KIF20A	psi-mi:“MI:0914”(association)	0.350
SIKE1	ALDH7A1	psi-mi:“MI:0914”(association)	0.350
TSNAXIP1	DPP8	psi-mi:“MI:0914”(association)	0.350
FHIP2A	MED19	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (44): CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Biochemical Activity), CCDC186 (Proximity Label-MS), CCDC186 (Proximity Label-MS), CCDC186 (Affinity Capture-MS), CCDC186 (Proximity Label-MS), CCDC186 (Proximity Label-MS), CCDC186 (Affinity Capture-MS)

ESM2 similar proteins: A0PJP4, A0PJT0, A2VDP1, A4IFK7, D3ZUQ0, E9PSL7, O14578, O75665, P0C219, P49025, P97817, Q01850, Q0IHE5, Q14BN4, Q17QG3, Q28623, Q3LGD4, Q3SYW5, Q3URD3, Q3V079, Q4R3X1, Q4R7Y8, Q58A65, Q5DTM8, Q5EBL4, Q5R5R4, Q5VTR2, Q5ZJA3, Q5ZLS3, Q62172, Q62796, Q68CZ1, Q6AYA0, Q6DFC2, Q6DH86, Q6NRH3, Q6ZUS6, Q7Z3E2, Q86VS8, Q8BR07

Diamond homologs: Q5R9B3, Q7Z3E2, Q8C9S4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

130 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	111
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1120267	NM_018017.4(CCDC186):c.767C>G (p.Ser256Ter)	Pathogenic
253479	GRCh37/hg19 10q24.32-26.3(chr10:103288313-135512075)x3	Pathogenic

SpliceAI

2155 predictions. Top by Δscore:

Variant	Effect	Δscore
10:114125913:AT:A	donor_gain	1.0000
10:114125913:ATCCT:A	donor_gain	1.0000
10:114125926:G:GA	donor_gain	1.0000
10:114126101:TTATT:T	acceptor_gain	1.0000
10:114126102:TATT:T	acceptor_gain	1.0000
10:114126103:ATTC:A	acceptor_loss	1.0000
10:114126104:TT:T	acceptor_gain	1.0000
10:114126104:TTC:T	acceptor_loss	1.0000
10:114126105:TC:T	acceptor_loss	1.0000
10:114126106:C:CC	acceptor_gain	1.0000
10:114126106:CTGCA:C	acceptor_loss	1.0000
10:114126107:T:A	acceptor_loss	1.0000
10:114127456:CATA:C	donor_gain	1.0000
10:114127459:A:AC	donor_gain	1.0000
10:114127460:C:CG	donor_gain	1.0000
10:114127460:CT:C	donor_gain	1.0000
10:114127460:CTTT:C	donor_gain	1.0000
10:114127460:CTTTG:C	donor_gain	1.0000
10:114127471:T:A	donor_gain	1.0000
10:114127482:T:TA	donor_gain	1.0000
10:114127482:TCC:T	donor_gain	1.0000
10:114127667:GGACC:G	acceptor_gain	1.0000
10:114127668:GACC:G	acceptor_gain	1.0000
10:114127670:CC:C	acceptor_gain	1.0000
10:114127670:CCCT:C	acceptor_loss	1.0000
10:114127671:CC:C	acceptor_gain	1.0000
10:114127672:C:CC	acceptor_gain	1.0000
10:114129972:C:CC	acceptor_gain	1.0000
10:114131146:CCTTG:C	donor_gain	1.0000
10:114131215:T:C	donor_gain	1.0000

AlphaMissense

5963 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:114125927:C:G	A858P	1.000
10:114127511:A:C	F781L	1.000
10:114127511:A:T	F781L	1.000
10:114127513:A:G	F781L	1.000
10:114127551:A:G	L768P	1.000
10:114125219:A:G	L874P	0.999
10:114125905:A:G	L865P	0.999
10:114125932:A:G	L856S	0.999
10:114125956:A:G	L848P	0.999
10:114127488:A:G	L789P	0.999
10:114127500:T:G	H785P	0.999
10:114127512:A:C	F781C	0.999
10:114127512:A:G	F781S	0.999
10:114127533:C:G	R774P	0.999
10:114127537:C:G	A773P	0.999
10:114127572:A:G	L761S	0.999
10:114132056:A:G	L595P	0.999
10:114132077:A:G	L588P	0.999
10:114125189:A:G	L884P	0.998
10:114125898:A:C	N867K	0.998
10:114125898:A:T	N867K	0.998
10:114125902:T:A	K866I	0.998
10:114125914:T:G	D862A	0.998
10:114125915:C:G	D862H	0.998
10:114125923:A:T	V859D	0.998
10:114127467:T:A	K796I	0.998
10:114127501:G:C	H785D	0.998
10:114127543:C:G	A771P	0.998
10:114127547:T:A	Q769H	0.998
10:114127547:T:G	Q769H	0.998

dbSNP variants (sampled 300 via entrez): RS1000014741 (10:114141252 C>G), RS1000273737 (10:114123711 A>C,G), RS1000283398 (10:114120654 C>G), RS1000321418 (10:114153638 T>C), RS1000321755 (10:114166467 T>C), RS1000364733 (10:114128759 A>G), RS1000385276 (10:114153980 C>T), RS1000425800 (10:114160033 G>A), RS1000455414 (10:114160297 C>A,G,T), RS1000652688 (10:114166268 C>G,T), RS1000761023 (10:114158700 T>C), RS1000854980 (10:114170743 G>A,T), RS1000898652 (10:114135421 T>C), RS1000907124 (10:114171086 C>A,T), RS1000943604 (10:114126941 A>T)

Disease associations

OMIM: gene MIM:619249 | disease phenotypes:

GenCC curated gene-disease

Mondo (3): microcephaly (MONDO:0001149), hypothyroidism (MONDO:0005420), pulmonary valve stenosis (MONDO:0006936)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009391_455	Metabolite levels	9.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010521	phosphocreatine measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D007037	Hypothyroidism	C19.874.482
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D011666	Pulmonary Valve Stenosis	C14.280.484.716; C14.280.955.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Formaldehyde	decreases expression, increases expression	2
Cyclosporine	increases expression	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
trichostatin A	decreases expression	1
methylparaben	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression	1
jinfukang	decreases expression	1
Bortezomib	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Vorinostat	decreases expression	1
Leflunomide	increases expression	1
Benzo(a)pyrene	decreases methylation	1
Ethyl Methanesulfonate	increases expression	1
Fluorouracil	increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	increases expression, affects cotreatment	1
Testosterone	decreases expression	1
Thimerosal	decreases expression	1
Thiram	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Urethane	increases expression	1
Vincristine	decreases expression	1

Clinical trials (associated diseases)

163 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001730	PHASE4	COMPLETED	Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
NCT00111735	PHASE4	UNKNOWN	Thyroxine Titration Study
NCT00206375	PHASE4	TERMINATED	Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism
NCT00565864	PHASE4	COMPLETED	Neurocognitive and Metabolic Effects of Mild Hypothyroidism
NCT01379170	PHASE4	UNKNOWN	Thyroid Study Type 2 Diabetes Mellitus (T2DM)
NCT01536678	PHASE4	COMPLETED	Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers
NCT01647750	PHASE4	COMPLETED	Study of Optimal Replacement of Thyroxine in the Elderly
NCT01769157	PHASE4	COMPLETED	Effects of L-carnitine on Hypothyroidism
NCT01831869	PHASE4	UNKNOWN	Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism
NCT01848171	PHASE4	UNKNOWN	Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism
NCT01921452	PHASE4	COMPLETED	Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit
NCT02280330	PHASE4	COMPLETED	Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months
NCT02512978	PHASE4	UNKNOWN	Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)
NCT02577367	PHASE4	WITHDRAWN	Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding
NCT02917863	PHASE4	UNKNOWN	Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism
NCT03342001	PHASE4	COMPLETED	Hypothyroidism Treated With Calcitonin
NCT03631771	PHASE4	WITHDRAWN	Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT03779906	PHASE4	TERMINATED	Thyroid Function of Pediatric Subjects Following Isovue® Administration
NCT04747275	PHASE4	TERMINATED	Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients
NCT04878614	PHASE4	TERMINATED	Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding
NCT05247476	PHASE4	UNKNOWN	Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients.
NCT06073665	PHASE4	RECRUITING	Dosing of LT4 in Older Individuals
NCT06096454	PHASE4	UNKNOWN	Effect of Life Style Modification and Metformin on Hypothyroidism With Insulin Resistance
NCT01204359	PHASE3	UNKNOWN	The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
NCT01800617	PHASE2	COMPLETED	A Study of T3 Therapy in Patients With Hypothyroidism
NCT01916304	PHASE2	COMPLETED	Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation
NCT03627611	PHASE2	COMPLETED	Identification of Non-responders to Levothyroxine Therapy
NCT04124705	PHASE2	COMPLETED	A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants
NCT04782856	PHASE2	COMPLETED	Energy Metabolism in Thyroidectomized Patients
NCT05412979	PHASE2	COMPLETED	A Study Evaluating the Safety and Efficacy of Hormone Replacement Therapy With ST-1891 Compared to Levothyroxine in Patients With Primary Hypothyroidism
NCT05712421	PHASE2	COMPLETED	A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism
NCT05733078	PHASE2	UNKNOWN	Effect of Vitamin C Supplementation in Patients With Primary Hypothyroidism
NCT05804149	PHASE2	COMPLETED	Effect of Acupuncture and Low Caloric Diet on Primary Hypothyroidism and Irregular Menstruation in Infertile Women
NCT05823012	PHASE2	COMPLETED	Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT00001639	Not specified	COMPLETED	Evaluation of Patients With Unresolved Chromosome Abnormalities
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT01565005	Not specified	COMPLETED	Microcephaly Genetic Deficiency in Neural Progenitors
NCT02510170	Not specified	COMPLETED	Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
NCT02741882	Not specified	COMPLETED	Zika and Microcephaly: Case-control Study